Jafry Syed A. 4

What Happened

• Syed A. Jafry, a Director of Zimmer Biomet Holdings, Inc. (ZBH), was granted a total of 2,392.624 derivative stock units on May 22, 2026. The grants consist of 875.350 phantom stock units and 1,517.274 restricted stock units (RSUs). Each unit has a conversion ratio of 1-for-1 into company common stock and the reported acquisition price is $0.00 (no cash paid).

Key Details

• Transaction date: May 22, 2026; Form 4 filed May 27, 2026 (filed within the normal Form 4 reporting window given the holiday calendar).
• Grants: 875.350 phantom stock units (accrued under the Deferred Compensation Plan for Non-Employee Directors) and 1,517.274 RSUs; combined = 2,392.624 units.
• Price: $0.00 reported (award/grant; no purchase price).
• Conversion: Derivative securities convert 1-for-1 into common shares (Footnote F2).
• Settlement/deferral: Phantom units will be settled in shares within 60 days after the director ceases service (F3). RSUs are 100% vested immediately but are subject to mandatory deferral until the later of (a) the director’s termination of service or (b) three years after the grant date (F5). Footnote F4 notes 21.697 phantom units included from dividend reinvestment.
• Filing timeliness: Filed May 27 for a May 22 grant; appears timely given business-day counting and the U.S. holiday calendar.

Context

• These awards are derivative/compensation grants (not open-market purchases or sales). Phantom stock units and RSUs typically convert into common shares later per plan rules, so they do not represent an immediate open-market investment or sale.
• Such grants are common for non-employee directors as part of board compensation; they are disclosures of compensation-related equity awards rather than trading activity by an insider.